Financial Data and Key Metrics Changes - United Therapeutics reported record total revenues of $800 million for Q3 2025, representing a 7% growth from Q3 2024 [8] - The company is guiding for a $4 billion revenue run rate by 2027, indicating strong future growth expectations [7][33] Business Line Data and Key Metrics Changes - Continued year-over-year growth in Tyvaso and Orenitram sales, driven by patient demand and effective commercial strategy [8] - Tyvaso sales demonstrated double-digit revenue growth, with no material impact from the launch of Eutrepia [8] - The launch of Tyvaso DPI 80 g cartridges is expected to enhance patient convenience and dosing flexibility [9][49] Market Data and Key Metrics Changes - The company is experiencing strong patient shipments and an increase in the number of prescribers, indicating robust market demand [36] - The TETON 2 study results are anticipated to broaden the therapeutic reach into respiratory diseases, potentially accelerating growth [11] Company Strategy and Development Direction - United Therapeutics is focused on expanding its product portfolio for pulmonary fibrosis and pulmonary hypertension, with significant investments in clinical trials [6][7] - The company is actively engaged in business development and anticipates partnerships with major pharmaceutical companies due to its strong data in pulmonary disease [7][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth profile of Tyvaso and the potential for increased diagnoses of IPF patients following the TETON 2 results [17][18] - The company is optimistic about the synergy between ralinepag and treprostinil, which could enhance treatment options for patients [23][24] Other Important Information - The Remunity Pro pump was launched to improve the experience of parenteral therapy for patients [11] - The company is preparing for upcoming conferences to discuss its product pipeline and business activities [4] Q&A Session Summary Question: Are you seeing an uptick in diagnoses of IPF patients due to TETON 2 results? - Management noted that while physicians are discussing more aggressive screening for pulmonary hypertension in IPF patients, it is still too early to confirm an uptick in diagnoses [15][18] Question: What is the market opportunity for ralinepag? - Management highlighted that ralinepag is exceeding expectations, with strong enrollment in the outcomes trial and best-in-class results for six-minute walk distances [21][22] Question: Can you elaborate on potential partnerships related to Tyvaso IPF data? - Management indicated that skepticism about the drug's efficacy in pulmonary fibrosis is changing, and they are open to partnerships to expand the drug's reach globally [26][30] Question: What are the commercial dynamics for Tyvaso recently? - Management reported strong patient shipments and prescriber growth, with no significant impact from Eutrepia's launch, expecting continued growth in both PAH and PH-ILD [32][36] Question: What is the status of the TETON PPF enrollment and regulatory path? - Management confirmed that enrollment is about halfway through and they are working with the FDA to expedite the regulatory review process [41][43] Question: What are the launch plans for the new 80 g cartridge for Tyvaso DPI? - Management stated that the 80 g cartridge will launch within 30 to 60 days, aimed at enhancing patient convenience and dosing [49]

Financial Data and Key Metrics Changes - Consolidated earnings for Q3 2025 were reported at $1.14 per share, an increase from $1.09 per share in the same quarter last year [3][8] - The electric company achieved net income of $243 million, or $1.20 per diluted share, compared to $225 million, or $1.20 per share last year [8][9] - The holding company reported a loss of $12 million, or $0.06 per diluted share, compared to a loss of $6 million, or $0.03 per share last year [9] Business Line Data and Key Metrics Changes - The main driver for the increase in net income was the recovery of capital investments, despite higher O&M and income taxes [9] - Year-over-year customer growth was just under 1% in Q3, with weather-normalized load growth at 6.5% [9][10] - The company expects total retail normalized load growth of approximately 7.5% in 2025 [9] Market Data and Key Metrics Changes - Oklahoma customers will see a decrease in their monthly bill due to a reduction in the fuel cost adjustment, averaging $6.75 lower per month [5] - The company has experienced load growth that surpasses national trends, particularly from data centers [5][6] Company Strategy and Development Direction - The company is focused on maintaining low rates to sustain growth and has a strong capital investment plan, including a $250 million project for the Fort Smith to Muskogee transmission line [10][11] - The company is negotiating with existing bidders and anticipates issuing more RFPs to address future generation needs [4][10] - The company aims to achieve a consolidated earnings growth rate of 5%-7% based on the midpoint of its 2025 guidance [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering results in the top half of the earnings guidance range for 2025 [8][12] - The company highlighted strong local economies and job growth in Oklahoma and Arkansas, contributing to its operational success [7][10] - Management emphasized the importance of affordability and operational excellence in driving customer demand and business growth [6][7] Other Important Information - The company has a strong balance sheet, which is considered a competitive advantage [12] - The company is in serious negotiations regarding data center load, with expectations for announcements in the near future [6][65] Q&A Session Summary Question: CapEx needs and RFP process - Management anticipates approval for the pre-approval request soon and plans to layer in additional filings and RFPs as needed [18][20] Question: Regulatory constructs and ROE lag - Management indicated that they have a good track record on minimizing ROE lag and will provide guidance for next year in February [21][22] Question: 2025 SPP ITP plan and competitive position - Management acknowledged the robust SPP plan but noted that further milestones are needed before providing a firm outlook [31] Question: Data center project negotiations - Management confirmed ongoing negotiations and the requirement to file a large load tariff as part of the pre-approval settlement [32][65] Question: Load growth outlook for 2025 - Management clarified that the load growth outlook of 7.5% for 2025 is at the low end of the prior range due to timing issues with customer ramp-up [34] Question: Meeting capacity needs by 2030 - Management confirmed that they expect to meet some capacity needs from the current RFP and will file a new RFP to address the remaining shortfall [46] Question: Dividend growth rate - Management stated that the dividend growth rate is targeted to align with investment opportunities, aiming for a payout ratio of 65%-70% [55] Question: Rate filing cadence - Management confirmed that the philosophy regarding rate filings remains unchanged, with adjustments based on settlement agreements [56]

Financial Data and Key Metrics Changes - For Q3 2025, the company reported GAAP net income of $0.37 per share and distributable earnings (DE) of $0.24 per share, with DE prior to charge-offs at $0.48 per share, an increase of $0.03 from the prior quarter [4][15] - The book value remained stable at $20.99 per share, reflecting strong credit performance and loan resolutions executed above carrying values [16][17] - The company repurchased $16 million of common stock in Q3 at an average price of $18.69, and an additional $61 million in Q4, totaling nearly $140 million since the buyback program began in 2024 [16][18] Business Line Data and Key Metrics Changes - The company closed $1 billion in total investments during Q3, with 75% concentrated in multifamily and diversified industrial portfolios, and over 60% in international markets [9][10] - The loan portfolio is now 96% performing, with the impaired loan balance down 71% from last year's peak [13] - The company expects to close over $7 billion in new investments this year, diversifying the portfolio and enhancing credit composition [12] Market Data and Key Metrics Changes - Real estate fundamentals remain strong, with stable or improving demand and constrained new supply [6] - The company collected $1.6 billion in repayments during Q3, including significant repayments from large loans [12] - The San Francisco market is showing signs of recovery, with multifamily rents up 10% and office demand growing [13][14] Company Strategy and Development Direction - The company is focused on optimizing its balance sheet and enhancing competitiveness through improved cost of capital [5][7] - The strategy includes a deliberate rotation into sectors and markets best positioned in the current environment, leveraging a robust investment pipeline [12] - The company aims to capitalize on the recovery in market conditions and the return of liquidity to the CRE markets [6][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing recovery of the real estate credit market, noting improved credit quality and a robust pipeline of opportunities [36][42] - The company is not seeing spillover effects from broader economic weaknesses into the CRE market, indicating a more battle-tested environment [36] - Management remains optimistic about the potential for earnings uplift from the REO and impaired loan portfolios [47] Other Important Information - The company has a strong liquidity position of $1.3 billion and over $7 billion of available financing capacity [17] - The company has been active in refinancing and extending corporate debt, taking advantage of favorable capital market conditions [14][18] Q&A Session Summary Question: Can you provide more color on the recovery in transaction activity and liquidity in the CRE markets? - Management noted that liquidity has returned to both the U.S. and Europe, with a stronger recovery in the U.S. driven by a more established CMBS market [24] Question: What is the potential earnings uplift from the REO portfolio? - Management indicated that while specific numbers were not provided, there is significant opportunity to drive additional earnings as the portfolio is turned over [26] Question: How do you see the balance between originating new loans versus share buybacks? - Management stated that they continuously evaluate both options and have been active in buybacks when stock is trading at attractive levels [30] Question: What are the current fundamentals in the office market? - Management reported stability and improvement in the office market, with several upgrades in their office loans driven by increased leasing activity [54]

Financial Data and Key Metrics Changes - American Electric Power reported third quarter 2025 operating earnings of $1.80 per share, a decrease from $1.85 per share in the same period last year, primarily due to the prior year's sale of the onsite partners' distributed resources business [24][25] - Year-to-date operating earnings totaled $4.78 per share, up from $4.38 per share in 2024, representing an increase of approximately 9% year over year [25] - The company reaffirmed its 2025 full-year operating earnings range of $5.75 to $5.95 per share, guiding to the upper half of this range [9][34] Business Line Data and Key Metrics Changes - Significant commercial and industrial load growth of nearly 8% on a rolling 12-month basis as of September 30, 2025, compared to the same period last year [25] - The generation and marketing segment's performance was impacted by the prior year sale of the distributed resources business, but favorable energy margins helped support overall results [26] Market Data and Key Metrics Changes - AEP projects a system peak demand of 65 gigawatts by 2030, with a load growth of almost 76% in the next five years, driven by data centers and reshoring of manufacturing [10][11] - The company has secured 28 gigawatts of contracted load additions, up from 24 gigawatts previously reported, backed by energy service agreements or letters of agreement [10][11] Company Strategy and Development Direction - AEP announced an increased long-term operating earnings growth rate of 7% to 9% for 2026 to 2030, with an expected 9% CAGR over the five-year period [7][27] - The company is focused on a $72 billion capital plan, with over two-thirds directed towards transmission and generation to support load growth [30][34] - AEP is actively engaging with regulators and policymakers to achieve constructive outcomes that benefit both customers and shareholders [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and team, highlighting the importance of disciplined execution and strong cash flow from operations [36][37] - The company is committed to maintaining affordability for customers, forecasting average system residential customer rates to increase by approximately 3.5% annually through 2030, below the historical average inflation rate [21][35] Other Important Information - AEP has secured commission approvals for data center tariffs in Ohio and large load tariff modifications in Indiana, Kentucky, and West Virginia [11][16] - The company is exploring generation solutions, including participation in the early site permit process for small modular reactors in Indiana and Virginia [19][20] Q&A Session Summary Question: Drivers of earnings step up in 2028 - Management indicated that the capital plan peaking in 2027 and 2028, along with positive legislative outcomes, will drive earnings growth during that period [39][40] Question: Composition of equity needs - Management discussed the anticipated equity needs and potential for minority stake sell downs, indicating a proactive approach to funding growth [42][44] Question: Earnings growth in 2028 to 2030 - Management clarified that the guidance for 2028 to 2030 reflects year-over-year growth, with expectations to be at or above the high end of the range [49][64] Question: Strategy for data center load growth - Management expressed confidence in meeting transmission capacity needs for data centers, highlighting the competitive advantage of their 765 kV transmission network [71][73] Question: Balance between renewables and gas generation - Management emphasized a balanced approach to generation planning, aligning with state energy policies and customer preferences [75][76]

Financial Data and Key Metrics Changes - Consolidated earnings for the third quarter were reported at $1.14 per share, an increase from $1.09 per share in the previous year [3][8] - The electric company achieved net income of $243 million, or $1.20 per diluted share, compared to $225 million, or $1.20 per share last year [8][9] - Consolidated net income was $231 million, reflecting a year-over-year increase driven by capital investment recovery, despite higher operational costs [8][9] Business Line Data and Key Metrics Changes - The electric company’s performance was bolstered by increased recovery of capital investments, while the holding company reported a loss of $12 million, attributed to higher interest expenses [9][10] - Year-over-year customer growth was just under 1%, with weather-normalized load growth at 6.5% through the third quarter [9][10] Market Data and Key Metrics Changes - Oklahoma customers will see a decrease in their monthly bills due to a reduction in the fuel cost adjustment, averaging $6.75 lower per month [5][6] - The company has experienced load growth that surpasses national trends, particularly driven by demand from data centers [5][6] Company Strategy and Development Direction - The company is focused on maintaining low rates to sustain growth and has plans for significant capital projects, including a $250 million transmission line project [10][11] - The company aims to deliver a consolidated earnings growth rate of 5% to 7% based on the midpoint of its 2025 guidance [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering results in the top half of the earnings guidance range for 2025, citing strong operational execution and favorable regulatory outcomes [3][8] - The company is optimistic about future growth opportunities, particularly in the data center sector, and is actively negotiating with potential customers [6][66] Other Important Information - The company has updated its capital plan to include new projects aimed at addressing reliability and capacity issues [10][11] - The balance sheet remains strong, providing a competitive advantage in the industry [12] Q&A Session Summary Question: CapEx needs and RFP process acceleration - Management indicated that they anticipate approval for the pre-approval request soon and will layer in additional filings as needed [18][20] Question: Impact of new regulatory constructs on ROE - Management noted that they have a good track record on minimizing ROE lag and will provide guidance for next year in February [21][22] Question: 2025 SPP ITP plan and competitive position - Management acknowledged the robust plan but indicated that further milestones need to be met before providing a firm outlook [31] Question: Data center contract negotiations - Management confirmed that serious negotiations are ongoing and that any agreements would be followed by necessary filings for approval [66] Question: Long-term EPS CAGR outlook - Management expressed confidence in maintaining a solid growth outlook regardless of specific deals, emphasizing a consistent approach to guidance [71]

Financial Data and Key Metrics Changes - In Q3 2025, the company generated nearly $100 million in free cash flow, with gold and copper production reaching almost 82,000 ounces and 13.4 million pounds respectively [4] - The cash balance increased to over $560 million, allowing the company to fund the Thompson Creek Restart project while returning $32 million to shareholders through buybacks and dividends [4][19] - Adjusted net earnings for Q3 were $66 million, or $0.33 per share, benefiting from strong production and elevated metal prices [16] - Consolidated all-in sustaining costs on a byproduct basis were $1,652 per ounce in Q3, with expectations to remain near the low end of guidance for 2025 [16] Business Line Data and Key Metrics Changes - Mount Milligan produced over 32,500 ounces of gold and 13.4 million pounds of copper in Q3 2025, with all-in sustaining costs at $1,461 per ounce, a 14% increase from the previous quarter [12] - Öksüt achieved production of 49,000 ounces in Q3, exceeding expectations due to higher grades, with all-in sustaining costs at $1,473 per ounce, a 16% decrease compared to the last quarter [13][14] - The Molybdenum business unit sold approximately 3.1 million pounds at an average price of $24.42 per pound, but incurred a cash flow deficit due to spending on the Thompson Creek Restart [16][18] Market Data and Key Metrics Changes - The average realized price for gold was $3,178 per ounce and for copper was $3.73 per pound, reflecting the impact of existing streaming arrangements [16] - The company noted increased confidence in the U.S. steelmaking sector, which is beneficial for its molybdenum products [31] Company Strategy and Development Direction - The company is focused on a self-funded growth strategy, with significant investments planned for Mount Milligan and other projects, including a $186 million non-sustaining capital expenditure plan [7][8] - The Mount Milligan Pre-Feasibility Study (PFS) extended the mine life to 2045, with an average annual production forecast of 150,000 ounces of gold and 69 million pounds of copper from 2026 to 2042 [7][9] - The company is advancing sustainability initiatives, including a renewable diesel pilot project aimed at reducing greenhouse gas emissions [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving production guidance for both Mount Milligan and Öksüt, with expectations for strong production in Q1 2026 [28] - The company is monitoring the favorable environment for U.S.-based mining and potential strategic deals related to molybdenum [31][32] - Management emphasized the importance of optimizing operations and enhancing shareholder value through disciplined capital allocation [20][21] Other Important Information - The company has initiated a life-of-mine optimization study at Öksüt to evaluate the asset's full potential, including residual leaching and expanding the pit [14][15] - The company has returned over $95 million to shareholders through dividends and share buybacks year-to-date [18][19] Q&A Session Summary Question: What drove the lower recovery at Mount Milligan in Q3? - Management explained that the recovery was impacted by a higher ratio of pyrite to chalcopyrite than previously modeled, which affected the recovery rates [23][24] Question: Will Öksüt see strong grades in Q1 2026? - Management confirmed confidence in achieving production guidance and expects strong production in Q1 2026 due to positive reconciliation [28] Question: Is there potential for a strategic deal with the U.S. Government regarding molybdenum? - Management acknowledged the favorable environment for U.S. mining and indicated they are monitoring potential strategic opportunities, although no current deals are in place [31][32] Question: Will the life-of-mine optimization study at Öksüt require additional permitting? - Management stated that while modifications for residual leaching would be necessary, the study primarily focuses on managing accumulated inventories without significant new permitting requirements [38] Question: What is the plan for improving recoveries at Mount Milligan? - Management outlined that the PFS aims to create a mine plan that optimizes feed blending to improve recovery rates, with expectations to start seeing improvements in Q1 of the following year [40][41]

Financial Data and Key Metrics Changes - United Therapeutics reported record total revenues of $800 million for Q3 2025, representing a 7% growth from Q3 2024 [8] - The company is guiding for a $4 billion revenue run rate by 2027, indicating strong future growth expectations [7][33] Business Line Data and Key Metrics Changes - Continued year-over-year growth in Tyvaso and Orenitram sales, with Tyvaso showing double-digit revenue growth [8] - The launch of Tyvaso DPI is driving a shift in dosing behavior, with an increase in average dosing from nine breaths per treatment to twelve breaths equivalent [9] - New Tyvaso DPI 80-microgram cartridges will soon be launched, allowing patients to take 15 nebulized breaths in one single breath, enhancing convenience [9][49] Market Data and Key Metrics Changes - The company is experiencing no material impact from the launch of Eutrepia, with expectations of continued growth in both PAH and PH-ILD markets [34][36] - The TETON 2 study demonstrated unprecedented treatment benefits for inhaled treprostinil in patients with idiopathic pulmonary fibrosis, potentially broadening the therapeutic reach [11][22] Company Strategy and Development Direction - United Therapeutics is actively engaged in business development and anticipates partnerships with major pharmaceutical companies due to its strong data in pulmonary disease [7][22] - The company emphasizes its public benefit status, focusing on patient care while also considering shareholder interests [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth profile of Tyvaso, supported by favorable coverage decisions from major payers [11] - The company is optimistic about the potential for ralinepag, highlighting its long patent life and the possibility of combination therapies [22][24] Other Important Information - The Remunity Pro pump was launched to enhance the experience of parenteral therapy, designed based on feedback from healthcare providers and patients [12] - The company is preparing for upcoming conferences to present its scientific and commercial advancements [4] Q&A Session Summary Question: Are you seeing an uptick in diagnoses of IPF patients due to TETON 2 results? - Management noted that while physicians are discussing more aggressive screening for pulmonary hypertension in IPF patients, it is still too early to confirm any direct uptick in diagnoses [15][18] Question: Can you elaborate on the market opportunity for ralinepag? - Management highlighted that ralinepag is exceeding expectations, with strong enrollment in the outcomes trial and best-in-class results for six-minute walk distances [21][22] Question: What are the partnership expectations related to Tyvaso IPF data? - Management indicated that skepticism about the drug's efficacy in pulmonary fibrosis is changing, and they are open to partnerships to expand the drug's reach globally [26][30] Question: Can you discuss the commercial dynamics for Tyvaso recently? - Management reported strong patient shipments and prescriber growth, with no material impact from Eutrepia's launch, expecting continued growth in both PAH and PH-ILD [32][36] Question: What is the status of the 80 micrograms cartridge for Tyvaso DPI? - Management confirmed that the new cartridge will launch within 30-60 days, aimed at enhancing patient convenience and dosing flexibility [49]

Financial Data and Key Metrics Changes - Net sales increased by 7% to $244 million, driven by a 5% increase in net price and a 2% increase in volume [4][7][15] - Adjusted EBITDA increased by 16% to $59 million, with an adjusted EBITDA margin of 24.2%, up 170 basis points [4][7][15] - Gross profit margin expanded by 150 basis points to 51.2% [4][15] - Cash flow from operations year-to-date was $283 million, compared to $276 million in the previous year [20] Business Line Data and Key Metrics Changes - North American net sales increased by 7% to $208 million, with a 7% increase in net price realization and stable volume [16][17] - European and rest of the world net sales increased by 11% to $36 million, with an 8% increase in volume offsetting a 1% reduction in net price realization [17][18] - Adjusted segment income margins in Europe increased to 18.5% from 8.4% a year ago [18] Market Data and Key Metrics Changes - Strong demand trends were reported, particularly in Canada, which saw over 20% growth [28] - The U.S. market experienced improved out-the-door sales growth rates for Hayward products, especially in September [8][26] - The aftermarket model remains resilient, with approximately 85% of sales aligned with serving existing installed base needs [8][9] Company Strategy and Development Direction - The company is focusing on expanding customer relationships, developing innovative products, and leveraging operational excellence [5][6] - Strategic initiatives include tariff mitigation actions and investments in advanced engineering and product development [11][12] - The company is also pursuing additional acquisition opportunities in residential and commercial pool sectors [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the dynamic environment and raised full-year guidance for net sales and adjusted EBITDA [6][22] - The company expects net sales to increase approximately 4% to 5.5% for the full year, with adjusted EBITDA projected to increase by 5% to 7% [22][23] - Management noted that the macroeconomic and tariff environment continues to evolve, but they remain positive about long-term growth in the pool industry [24] Other Important Information - The company has reduced net leverage to 1.8 times, the lowest level in nearly four years, providing enhanced financial flexibility [5][19] - The board authorized a share repurchase program of up to $450 million over three years [21] Q&A Session Summary Question: How did the season progress since July, and where did you see the upside in the third quarter? - Management noted strong sales out demand, particularly in September, and highlighted improved performance in Canada and Europe [26][28] Question: How do you think about the early buy program relative to the market being flat? - Management indicated that the early buy program is tracking expectations and that they are managing price increases carefully to mitigate inflation impacts [30][31] Question: Can you discuss your investments in new products and how they are impacting sales? - Management emphasized targeted investments in engineering and new product development, particularly with the OmniX platform, which is expected to drive future growth [34][36] Question: What are your capital allocation priorities moving forward? - Management stated that they will focus on organic capex, M&A opportunities, and share repurchases, with an emphasis on automation and supply chain improvements [49][50] Question: How are you addressing the impact of tariffs and supply chain realignment? - Management reported significant progress in reducing exposure to China and successfully applying for tariff refunds, which positively impacted margins [82][84]

Financial Data and Key Metrics Changes - The company reported total net sales of $175.3 million for Q3 2025, a decrease of $4.2 million or 2.3% from Q3 2024 [17] - Adjusted EBITDA was $49.5 million, an increase of $6.3 million or 14.6% from the previous year, with an adjusted EBITDA margin of 28.2%, up approximately 410 basis points from Q3 2024 [21] - Free cash flow for the quarter was $59.2 million, $8.1 million lower than Q3 2024, primarily due to unfavorable working capital and a one-time cash contribution related to the pension plan settlement [31] Business Line Data and Key Metrics Changes - Software solutions net sales grew by 10.3% year-over-year, accounting for approximately 52% of total sales in the quarter [5][17] - ActiveDisclosure saw a significant sales growth of approximately 26%, while ArcSuite's growth was more modest at around 10% due to overlapping benefits from previous regulatory changes [7][9] - Venue's sales increased by approximately 3% compared to the same quarter last year, benefiting from stable demand across public and private companies [9][10] Market Data and Key Metrics Changes - The capital markets transactional revenue was reported at $41.8 million, down $3.5 million from Q3 2024, primarily due to lower foreign issuer transaction volumes [25][26] - The company experienced a 25% year-over-year increase in U.S. IPO activity, although this was offset by a soft market for foreign issuance transactions [25][26] - The ongoing government shutdown has impacted capital markets deal activity, delaying many planned transactions [12][13] Company Strategy and Development Direction - The company is focused on transforming into a software-centric business, aiming to derive approximately 60% of total sales from software solutions by 2028 [6] - Continued investments in modernization and innovation of software products are expected to drive future growth [11] - The company is preparing its 2026 operating plan and extending its long-range plan through 2030, with an emphasis on growing software solutions and operational transformation [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to perform well despite the uncertainty caused by the government shutdown, highlighting strong client relationships and market leadership [14][37] - The outlook for Q4 2025 includes expected consolidated net sales in the range of $150 million to $160 million, reflecting a slight reduction compared to the previous year [33] - Management anticipates that the government shutdown will lead to a temporary softening in capital markets transactional revenue, with expectations for recovery once operations resume [34][36] Other Important Information - The company completed the termination of its primary defined benefit pension plan, resulting in a non-cash pre-tax settlement charge of $82.8 million [15][16] - The company repurchased approximately 659,000 shares of common stock during Q3 for $35.5 million, with $114.5 million remaining on its current stock repurchase authorization [32] Q&A Session Summary Question: Impact of government shutdown on Q4 margins - Management indicated that the lower transactional revenue would negatively impact margins, but a healthcare recovery would help offset this [42][43] Question: SEC reporting frequency changes - Management is monitoring developments regarding potential changes to SEC reporting frequency and believes their subscription model provides insulation from most impacts [50][52] Question: Resurgence of SPAC IPOs - Management noted a decline in share of SPAC deals due to increased competition and a focus on quality deals [55][56] Question: Venue performance and timing of M&A deals - Management expressed optimism about Venue's performance and indicated that while the government shutdown has delayed some M&A deals, underlying activity remains strong [62][64] Question: Capital allocation priorities - Management reiterated that maintaining financial flexibility and being opportunistic with share repurchases are top priorities [76]

Banco Santander (Brasil) (NYSE:BSBR) Q3 2025 Earnings Call October 29, 2025 09:00 AM ET Company ParticipantsCamila Toledo - Head of Investor Relations and Market IntelligenceGustavo Schroden - Equity Research DirectorMario Leão - CEOMario Pierry - Managing DirectorJorge Kuri - International Client Advisor, Portfolio Manager, and VPNone - TranslatorYuri Fernandes - Executive DirectorGustavo Alejo - CFOCarlos Gomez - Head of LatAm Financial InstitutionsConference Call ParticipantsEduardo Nishio - Senior Equit ...